Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Hemoglobinuria
MeSH terms: Hemoglobinuria; Hemoglobinuria, Paroxysmal
Intervention: Pegcetacoplan; Soliris
Intervention description: Complement (C3) Inhibitor; Complement (C5) Inhibitor
Intervention MeSH terms: Eculizumab
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 80.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal
      Hemoglobinuria
    

Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  Primary diagnosis of PNH confirmed by high-sensitivity flow cytometry

          -  On treatment with eculizumab. Dose of eculizumab must have been stable for at least 3
             months prior to the Screening Visit

          -  Hb <10.5 g/dL at the Screening Visit

          -  Absolute reticulocyte count > 1.0x ULN at the Screening Visit

          -  Platelet count of >50,000/mm3 at the Screening Visit

          -  Absolute neutrophil count >500/mm3 at the Screening Visit

          -  Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus
             pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day
             1 dosing, or within 14 days after starting treatment with APL-2. Unless documented
             evidence exists that subjects are non-responders to vaccination as evidenced by titers
             or display titer levels within acceptable local limits

          -  Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the
             Screening and Day -28 Visit (Run-in Period) and must agree to use protocol defined
             methods of contraception for the duration of the study and 90 days after their last
             dose of study drug

          -  Males must agree to use protocol defined methods of contraception and agree to refrain
             from donating sperm for the duration of the study and 90 days after their last dose of
             study drug

          -  Willing and able to give informed consent

          -  Willing and able to self-administer APL-2 (administration by caregiver will be
             allowed)

          -  Have a body mass index (BMI) ≤35.0 kg/m2

        Exclusion Criteria:

          -  Active bacterial infection that has not resolved within 14 week of Day -28 (first dose
             of APL-2)

          -  Receiving iron, folic acid, vitamin B12 and EPO, unless the dose is stable, in the 4
             weeks prior to Screening

          -  Hereditary complement deficiency

          -  History of bone marrow transplantation

          -  History or presence of hypersensitivity or idiosyncratic reaction to compounds related
             to the investigational product or SC administration

          -  Participation in any other investigational drug trial or exposure to other
             investigational agent within 30 days or 5 half-lives (whichever is longer)

          -  Currently breast-feeding women

          -  Inability to cooperate or any condition that, in the opinion of the investigator,
             could increase the subject's risk of participating in the study or confound the
             outcome of the study

        This study includes cardiac safety evaluations. The following cardiac eligibility criteria
        are necessary to avoid confounding the cardiac safety outcomes:

          -  History or family history of Long QT Syndrome or torsade de pointes, unexplained
             syncope, syncope from an uncorrected cardiac etiology, or family history of sudden
             death

          -  Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty,
             stroke, cardiac surgery, or hospitalization for congestive heart failure within 3
             months or greater than Class 2 Angina Pectoris or NYHA Heart Failure Class >2

          -  QTcF > 470 ms, PR > 280 ms

          -  Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart
             Block unless the patient has an implanted pacemaker or implantable cardiac
             defibrillator (ICD) with backup pacing capabilities

          -  Receiving Class 1 or Class 3 antiarrhythmic agents, or arsenic, methadone, ondansetron
             or pentamidine at screening

          -  Receiving any other QTc-prolonging drugs (see Appendix 4 in Section 19.4), at a stable
             dose for less than 3 weeks prior to dosing

          -  Receiving prophylactic ciprofloxacin, erythromycin or azithromycin for less than one
             week prior to the first dose of study medication (must have a repeat screening ECG
             after one week of prophylactic antibiotics with QTcF < 470 ms)